Skip to Content

'
Xin Shelley Wang, MD, MPH

Present Title & Affiliation

Primary Appointment

Professor, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Wang, a professor in the Department of SymptomResearch, received her medical degree in China and practiced oncology there for10 years. Her research focuses on patient-reported outcomes (PRO) measurement,the impact of culture on symptom reporting, and clinical and translationalresearch on mechanism-driven interventions for cancer-related symptoms. Thesymptom assessment tools that she has developed and validated are widely usedin clinical practice and in research in China and other countries. She currentlyleads or participates in grants funded by the National Cancer Institute of theUS National Institutes of Health and by the American Cancer Society, focusingon the development of clinical methods to evaluate the symptomatic benefit ofvarious treatments. She has published more than 85 papers in peer-reviewedjournals, some in high-impact journals.

Research Interests

Dr. Wang's research focuses on the symptoms in cancer survivors or patients who are undergoing active treatment or who have advanced disease. She has been involved in the development and validation of patient-reported outcome (PRO) symptom assessment tools in cancer patients, with different diseases and languages. Among cancer patients undergoing aggressive therapies, such as concurrent chemoradiation, cancer surgery and stem cell transplant, her research in the area of cancer-related fatigue and other sickness symptoms has illustrated the important relationship between inflammatory cytokines and the development of major symptom burden, a better understanding of which might lead to potential mechanism-driven symptom control. Dr. Wang contributed on multiple aspects of methodological research on interpretation of the PRO tools. She has expertise for conducting longitudinal studies and interpreting the clinical meaningful of PRO data. These methods are applicable to clinical practice and clinical trials. Dr. Wang also contributed to the international clinical research and education on symptom science that investigated patient reported symptoms and their impact on functional status and quality of life. Her work provided a comparison of cross-cultural, cross-national similarities and differences in symptom reporting.

Office Address

The University of Texas MD Anderson Cancer Center
Department of Symptom Research
1515 Holcombe Blvd.
Unit Number: 1450
Houston, TX 77030
Room Number: FCT11.5080
Phone: (713) 745-3504
Fax: (713) 745-3475

Education & Training

Degree-Granting Education

2004 The University of Texas School of Public Health, Houston, TX, MPH, International Health
1984 Capital University of Medical Sciences, Beijing, China, MD, Medicine

Postgraduate Training

9/1989-12/1990 Chief Residency, Medical Oncology, Beijing Institute for Cancer Research, Beijing, China
7/1987-9/1989 Research Fellowship, Biochemistry, Beijing Institute for Cancer Research, Beijing, China
7/1987-9/1989 Clinical Residency, Medical Oncology, Beijing Institute for Cancer Research, Beijing, China
9/1986-7/1987 Clinical Residency, Hematology, First Hospital of Beijing Medical University, Beijing, China
9/1984-9/1986 Clinical Residency, Medical Oncology, Beijing Institute for Cancer Research, Beijing, China

Experience/Service

Academic Appointments

Associate Professor, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2006-8/2013
Associate Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2006-8/2013

Professional Memberships

American Society of Clinical Oncology (ASCO)
Member, 1999-present
American Society of Hematology (ASH)
Member, 2006-present
European Hematology Association
Member, 2007-2010
Psychoneuroimmunology Research Society
Member, 2008-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma. e-Pub 11/20/2014. PMID: 25248883.
2. Wang XS, Woodruff JF. Cancer-related and treatment-related fatigue. Gynecol Oncol. e-Pub 10/2014. NIHMSID: NIHMS640195.
3. Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 20(5):1366-74, 3/1/2014. e-Pub 1/14/2014. PMCID: PMC3947467.
4. Wang XS, Zhao F, Fisch MJ, O'Mara AM, Cella D, Mendoza TR, Cleeland CS. Prevalence and characteristics of moderate-to-severe fatigue: a multicenter study in cancer patients and survivors. Cancer 120(3):425-32, 2/1/2014. e-Pub 11/5/2013. PMCID: PMC3949157.
5. Barney BJ, Wang XS, Lu C, Liao Z, Johnson VE, Cleeland CS, Mendoza TR. Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer. Qual Life Res 22(8):2143-50, 10/2013. e-Pub 1/31/2013. PMCID: PMC3724766.
6. Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699-705, 7/2012. e-Pub 1/10/2012. PMCID: PMC3355215.
7. Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning I, Liu P, Allen PK, Azeem SS, Brown PD, Sharp HJ, Weksberg DC, Cleeland CS, Chang EL. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol 13(4):395-402, 4/2012. e-Pub 1/2012. PMCID: PMC3605896.
8. Cleeland CS, Wang XS, Shi Q, Mendoza TR, Wright SL, Berry MD, Malveaux D, Shah PK, Gning I, Hofstetter WL, Putnam JB, Vaporciyan AA. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol 29(8):994-1000, 3/10/2011. e-Pub 1/31/2011. PMCID: PMC3068055.
9. Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24(6):968-74, 8/2010. e-Pub 3/29/2010. PMCID: PMC2897921.
10. Wang XS, Cleeland CS, Mendoza TR, Yun YH, Wang Y, Okuyama T, Johnson VE. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst 102(10):732-738, 5/19/2010. e-Pub 3/26/2010. PMCID: PMC2873184.
11. Wang XS, Williams LA, Eng C, Mendoza TR, Shah NA, Kirkendoll KJ, Shah PK, Trask PC, Palos GR, Cleeland CS. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer 116(8):2053-63, 4/15/2010. e-Pub 2/2010. PMID: 20166216.
12. Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, Mobley GM, Cleeland CS. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced non-small cell lung cancer. Cancer 116(1):137-45, 1/2010. e-Pub 10/2009. PMCID: PMC3148693.
13. Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, Lee BN, Giralt SA. Serum IL-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 113(8):2102-9, 10/15/2008. PMCID: PMC2633777.
14. Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24(27):4485-91, 9/2006. PMID: 16983118.
15. Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeland CS. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer 101(8):1890-901, 10/2004. PMID: 15386315.
16. Wang XS, Giralt SA, Mendoza TR, Engstrom MC, Johnson BA, Peterson N, Broemeling LD, Cleeland CS. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J Clin Oncol 20(5):1319-28, 3/2002. PMID: 11870175.
17. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer 89(7):1634-46, 10/2000. PMID: 11013380.
18. Wang XS, Cleeland CS, Mendoza TR, Engstrom MC, Liu S, Xu G, Hao X, Wang Y, Ren XS. The effects of pain severity on health-related quality of life: a study of Chinese cancer patients. Cancer 86(9):1848-55, 11/1999. PMID: 10547560.
19. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186-96, 3/1999. PMID: 10091805.
20. Wang XS, Mendoza TR, Gao SZ, Cleeland CS. The Chinese version of the Brief Pain Inventory (BPI-C): its development and use in a study of cancer pain. Pain 67(2-3):407-16, 10/1996. PMID: 8951936.

Grant & Contract Support

Title: Effectiveness of Minocycline for Reducing Symptoms in Pancreatic Cancer Patients
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2012 - 8/31/2015
 
Title: Symptom Progression in Pancreatic Cancer
Funding Source: U. S. Cancer Pain Relief Committee
Role: Principal Investigator
Duration: 10/2008 - 9/2010
 
Title: Mechanisms of Symptoms of Multiple Myeloma and Its Therapy
Funding Source: NIH/NCI
Role: PI for Project 1
Principal Investigator: CS Cleeland
Duration: 9/18/2008 - 8/31/2014
 
Title: Reducing the Symptom Burden Produced by Aggressive Cancer Therapies
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: CS Cleeland
Duration: 7/1/2008 - 4/30/2015
 
Title: Inflammatory Cytokines Associated with Symptom Burden in NSCLC Patients Receiving CXRT
Funding Source: NIH
Role: Principal Investigator
Duration: 7/1/2008 - 6/30/2012
 
Title: MDASI-GI Validation and Clinical Utility in Patients with Gastrointestinal Cancers Receiving Chemotherapy
Funding Source: Pfizer Pharmaceuticals
Role: Principal Investigator
Duration: 3/2008 - 3/2010
 
Title: Neuropathic Pain Project - Colorectal Cancer Clinical Study
Funding Source: Astra Zeneca
Role: Co-Investigator
Principal Investigator: CS Cleeland
Duration: 11/26/2007 - 11/30/2012
 
Title: Neuropathic Pain Project - Multiple Myeloma
Funding Source: AstraZeneca
Role: Co-Investigator
Principal Investigator: Charles Cleeland
Duration: 11/26/2007 - 11/30/2012
 
Title: Single Agent ALIMTA in Poor Performance Status NSCLC
Funding Source: Eli Lilly and Company
Role: Investigator
Principal Investigator: Zinner, Ralph
Duration: 9/1/2005 - 9/1/2012
 
Title: Needs Assessment for Cancer Pain Relief Programs in Three Cancer Treatment Centers in Viet Nam
Funding Source: U. S. Cancer Pain Relief Committee
Role: Principal Investigator
Duration: 1/2003 - 5/2011
 
Title: Using a Novel System to Assess and Manage Post-Operative Pain and Other Symptoms in Patients with Lung Cancer
Funding Source: Pharmacia
Role: Co-Principal Investigator
Principal Investigator: CS Cleeland
Duration: 3/2002 - 2/2004
 
Title: Repeated Measure of Postoperative Fatigue: A Feasibility Study
Funding Source: Texas Medical Center
Role: Principal Investigator
Duration: 12/2000 - 1/2002
 
Title: Symptoms of Transplant Patients Near the End of Life
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: KO Anderson
Duration: 2/2000 - 1/2004

Last updated: 2/26/2015